MX381526B - Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. - Google Patents
Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.Info
- Publication number
- MX381526B MX381526B MX2016010892A MX2016010892A MX381526B MX 381526 B MX381526 B MX 381526B MX 2016010892 A MX2016010892 A MX 2016010892A MX 2016010892 A MX2016010892 A MX 2016010892A MX 381526 B MX381526 B MX 381526B
- Authority
- MX
- Mexico
- Prior art keywords
- chronic kidney
- kidney disease
- progression
- drug
- agent
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 206010062237 Renal impairment Diseases 0.000 abstract 3
- 230000005977 kidney dysfunction Effects 0.000 abstract 3
- UPSFNXFLBMJUQW-UHFFFAOYSA-N 5-hydroxy-1-methylimidazolidine-2,4-dione Chemical compound CN1C(O)C(=O)NC1=O UPSFNXFLBMJUQW-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un objetivo de la presente invención es proporcionar un agente farmacéutico el cual se administra a un paciente con enfermedad renal crónica en el cual el progreso de empeoramiento de la función renal es rápido con lo cual el progreso del síntoma se suprime o se mejora. La presente invención se refiere a un agente para suprimir el progreso de o para mejorar la enfermedad renal crónica que contiene 5-hidroxi-1-metilhidantoína como ingrediente activo. El agente farmacéutico de la presente invención mostró un efecto significativo en un paciente con enfermedad renal crónica donde el progreso de la disminución de la función renal es rápido. El presente agente farmacéutico es muy útil como un agente farmacéutico sumamente seguro el cual suprime o mejora el progreso del empeoramiento de la función renal de un paciente con enfermedad renal crónica rápidamente progresiva para el cual no ha habido un agente terapéutico efectivo que sea ingerible de manera simple y fácil. La figura más representativa de la invención es la número 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014034792 | 2014-02-26 | ||
| PCT/JP2015/055397 WO2015129750A1 (ja) | 2014-02-26 | 2015-02-25 | 慢性腎臓病の進行抑制又は改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010892A MX2016010892A (es) | 2016-11-17 |
| MX381526B true MX381526B (es) | 2025-03-12 |
Family
ID=54009065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010892A MX381526B (es) | 2014-02-26 | 2015-02-25 | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9801858B2 (es) |
| EP (1) | EP3111934B1 (es) |
| JP (1) | JP6509729B2 (es) |
| KR (1) | KR102311915B1 (es) |
| CN (2) | CN106029067A (es) |
| AU (1) | AU2015223908C1 (es) |
| CA (1) | CA2940003C (es) |
| DK (1) | DK3111934T3 (es) |
| ES (1) | ES2899889T3 (es) |
| MX (1) | MX381526B (es) |
| TW (1) | TWI646960B (es) |
| WO (1) | WO2015129750A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7146194B2 (ja) | 2017-06-13 | 2022-10-04 | 国立研究開発法人国立がん研究センター | 発がん抑制剤 |
| JP7370321B2 (ja) * | 2017-06-26 | 2023-10-27 | キボー バイオテック、インク | 腎疾患を有し、および標準治療の処置を受ける患者の腎機能を維持し、および改善するための方法 |
| CN110372614B (zh) * | 2019-07-03 | 2020-09-29 | 山东师范大学 | 一种四氢喹喔啉类化合物及制备方法与应用 |
| EP4082549A4 (en) * | 2019-12-23 | 2023-09-06 | Toray Industries, Inc. | MEDICATION TO PREVENT DEATH FROM DIALYSIS SESSION OR KIDNEY DISEASE |
| WO2023277521A1 (ko) * | 2021-07-02 | 2023-01-05 | 주식회사 경보제약 | ５－히드록시－１－메틸이미다졸리딘－２，４－디온 화합물을 유효성분으로 포함하는 동물용 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0238588B2 (ja) | 1981-01-06 | 1990-08-31 | Nippon Zoki Pharmaceutical Co | Shinkihidantoinkagobutsu |
| US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| JP2678499B2 (ja) * | 1989-08-09 | 1997-11-17 | 日本臓器製薬 株式会社 | 尿毒症毒素低下剤 |
| TWI353979B (en) | 2002-04-10 | 2011-12-11 | Nippon Zoki Pharmaceutical Co | Novel crystal form of 5-hydroxy-1-methylhydantoin |
| US8575175B2 (en) * | 2008-07-23 | 2013-11-05 | Toray Industries, Inc. | Therapeutic agent for chronic renal failure |
-
2015
- 2015-02-25 US US15/122,082 patent/US9801858B2/en not_active Expired - Fee Related
- 2015-02-25 MX MX2016010892A patent/MX381526B/es unknown
- 2015-02-25 AU AU2015223908A patent/AU2015223908C1/en not_active Ceased
- 2015-02-25 JP JP2015528795A patent/JP6509729B2/ja active Active
- 2015-02-25 CN CN201580010701.6A patent/CN106029067A/zh active Pending
- 2015-02-25 TW TW104106006A patent/TWI646960B/zh active
- 2015-02-25 EP EP15755704.2A patent/EP3111934B1/en active Active
- 2015-02-25 ES ES15755704T patent/ES2899889T3/es active Active
- 2015-02-25 DK DK15755704.2T patent/DK3111934T3/da active
- 2015-02-25 WO PCT/JP2015/055397 patent/WO2015129750A1/ja not_active Ceased
- 2015-02-25 CN CN202010607108.2A patent/CN111658641A/zh active Pending
- 2015-02-25 CA CA2940003A patent/CA2940003C/en active Active
- 2015-02-25 KR KR1020167019383A patent/KR102311915B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170065563A1 (en) | 2017-03-09 |
| DK3111934T3 (da) | 2021-11-15 |
| AU2015223908B2 (en) | 2019-12-12 |
| ES2899889T3 (es) | 2022-03-15 |
| JP6509729B2 (ja) | 2019-05-08 |
| EP3111934A4 (en) | 2017-10-11 |
| CN111658641A (zh) | 2020-09-15 |
| KR102311915B1 (ko) | 2021-10-13 |
| CN106029067A (zh) | 2016-10-12 |
| JPWO2015129750A1 (ja) | 2017-03-30 |
| CA2940003C (en) | 2021-11-16 |
| TWI646960B (zh) | 2019-01-11 |
| AU2015223908A1 (en) | 2016-09-01 |
| EP3111934B1 (en) | 2021-09-08 |
| AU2015223908C1 (en) | 2020-12-03 |
| WO2015129750A1 (ja) | 2015-09-03 |
| MX2016010892A (es) | 2016-11-17 |
| US9801858B2 (en) | 2017-10-31 |
| NZ724285A (en) | 2021-01-29 |
| TW201540300A (zh) | 2015-11-01 |
| EP3111934A1 (en) | 2017-01-04 |
| KR20160118234A (ko) | 2016-10-11 |
| CA2940003A1 (en) | 2015-09-03 |
| AU2015223908A2 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201692392A1 (ru) | Новая лекарственная форма мелоксикама | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX381526B (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| MX381311B (es) | Método para el tratamiento de prurito y/o comezón. | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
| EA201691562A2 (ru) | Фильтры для инфузионных наборов | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| AU2017904360A0 (en) | Dosage Regime for Treatment of Kidney Disease | |
| AU2017902795A0 (en) | Dosage Regime for Treatment of Kidney Disease | |
| AU2017902717A0 (en) | Dosage Regime for Treatment of Kidney Disease | |
| EA201691599A1 (ru) | Комбинация таурина и рацеметионина для лечения заболеваний печени |